Ocular Therapeutix Q3 2026 Results: Net Loss of $94.8M, Loss Widens
Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.
- Key figure
- Net loss $94.8M